Familial Cancer

, Volume 1, Issue 1, pp 57–60

Cancer risk in mismatch repair gene mutation carriers

  • Patrice Watson
  • Henry T. Lynch
Article

Abstract

Optimally accurate and valid estimates of cancer risk in genetically-defined subgroups requires population-based research. For rare genetic traits, very large studies are needed. Such is the case in hereditary nonpolyposis colorectal cancer syndrome (HNPCC), caused by mutations in mismatch repair (MMR) genes. A potentially more efficient approach is genotyped-proband design (GPD), in which probands are genotyped and the phenotypes of their relatives are investigated. However, to date most information comes from registry-based studies, where ascertainment bias makes interpretation difficult. Development in testing technology will lead to more identified mutation carriers, producing a clinical imperative to estimate risk, despite these problems. We reviewed the available results, and concluded that male mutation carriers have a lifetime colorectal cancer risk of 74% or more; female mutation carriers have a lower risk which is still many times higher than the risk in the general population. Risk is highest between the ages of 40 and 60, but considerable even before age 40. Lifetime endometrial cancer risk is 42% or more; the highest incidence is between age 40 and 60, and diagnosis before the age of 35 is rare. MMR mutation carriers are at elevated risk for ovarian, gastric, urologic tract, small bowel, hepatobiliary tract cancer, and for brain tumors. The risk of these cancer types is much lower than the risk for colorectal and endometrial cancer, but accurate, especially age-related estimates of risk are not available. Prevention strategies depend on estimates of age-specific risk. Clearly, multicenter studies to obtain such estimates are needed.

cancer risk colorectal cancer endometrial cancer HNPCC Lynch syndrome MMR mutations 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lynch HT, de la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet 1999; 36: 801-18.Google Scholar
  2. 2.
    Salovaara R, Loukola A, Kristo P et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18: 2193-200.Google Scholar
  3. 3.
    Gail MH, Pee D, Benichou J, Carroll R. Designing studies to estimate the penetrance of an identified autosomal dominant mutation: cohort, case-control, and genotyped-proband designs. Genet Epidemiol 1999; 16: 15-39.Google Scholar
  4. 4.
    Wijnen J, de Leeuw W, Vasen H et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999; 23: 142-4.Google Scholar
  5. 5.
    Jäger AC, Bisgaard ML, Myrhoj T et al. Reduced frequency of extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. Am J Hum Genet 1997; 61: 129-38.Google Scholar
  6. 6.
    Demographic Analysis Section, Division of Cancer Cause and Prevention National Cancer Institute. Surveillance, epidemiology, and end results: incidence and mortality data, 1973-77. Young JL Jr, Percy CL, Asire AJ (eds): NIH Publication No. 81-2330, 66-88. National Cancer Institute Monograph 57. Bethesda, Maryland: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1981.Google Scholar
  7. 7.
    Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71: 677-85.Google Scholar
  8. 8.
    Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-8.Google Scholar
  9. 9.
    Vasen HFA, Wijnen JT, Menko FH et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020-7.Google Scholar
  10. 10.
    Dunlop MG, Farrington SM, Carothers AD et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6: 105-10.Google Scholar
  11. 11.
    Aarnio M, Mecklin JP, Aaltonen LA et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64: 430-3.Google Scholar
  12. 12.
    Vasen HFA, Mecklin J-P, Meera Khan P, Lynch HT. The international collaborative group on hereditary nonpolyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424-5.Google Scholar
  13. 13.
    Watson P, Vasen HFA, Mecklin J-P et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96: 516-20.Google Scholar
  14. 14.
    Risinger JI, Barrett JC, Watson P et al. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal cancer syndrome. Cancer 1996; 77: 1836-43.Google Scholar
  15. 15.
    Boyd J, Rhei E, Federici MG et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 1999; 53: 87-91.Google Scholar
  16. 16.
    Lynch HT, Smyrk TC. Hereditary colorectal cancer. Semin Oncol 1999; 26: 478-84.Google Scholar
  17. 17.
    Burke W, Petersen G, Lynch P et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I. Hereditary nonpolyposis colon cancer. JAMA 1997; 277: 915-9.Google Scholar
  18. 18.
    Park J-G, Park YJ, Wijnen JT, Vasen HFA. Gene-environment interaction in hereditary nonpolyposis colorectal cancer with implications for diagnosis and genetic testing. Int J Cancer 1999; 82: 516-9.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Patrice Watson
    • 1
  • Henry T. Lynch
    • 2
  1. 1.Department of Preventive MedicineCreighton University School of MedicineOmahaUSA
  2. 2.Department of Preventive MedicineCreighton University School of MedicineOmahaUSA

Personalised recommendations